Efficacy,cost-effectiveness,and safety analysis of cefoperazone-sulbactam in the treatment of community-acquired pneumonia before and after centralized procurement
AIM To compare the effectiveness,cost-effectiveness,and safety of cefoperazone-sulbactam before and after the implementation of centralized drug procurement in the treatment of community-acquired pneumonia.METHODS A retrospective analysis was conducted on the real-world data of cefoperazone-sulbactam used in treating patients with community-acquired pneumonia in the period before(referred to as pre-procurement,n=71)from January to June 2022 and after(referred to as post-procurement,n=80)from January to June 2023 in the hospital.The collected data were summarized and analyzed to evaluate the effectiveness,cost-effectiveness,and safety of cefoperazone-sulbactam before and after centralized drug procurement in the community-acquired pneumonia setting.RESULTS The clinical effectiveness rates before and after procurement were 83.10％and 60.00％,respectively,with a statistically significant difference(P＜0.01).The bacterial clearance rates were 44.44％and 28.57％,respectively,with no statistically significant difference(P＞0.05).After procurement,there was a significant decrease in total treatment cost,cost per person-day,antibiotic cost,medication cost,and medication cost ratio(P＜0.05).The incremental cost-effectiveness ratio after procurement is 194.09.The incidence of adverse reactions before and after procurement was 4.29％and 5.00％,respectively,with no statistically significant difference(P＞0.05).CONCLUSION The clinical efficacy of cefoperazone after collection is slightly lower than that before collection,but there is no significant difference in bacterial clearance rate.However,there are significant economic advantages after procurement,effectively reducing the financial burden on patients and saving medical costs.There is no significant difference in the incidence of adverse reactions between the 2 groups.
centralized drug procurementcefoperazone-sulbactamcommunity-acquired pneumoniaeffectivenesscost-effectiveness
国家科技期刊平台
NSTL
万方数据
